Neptune blasts off with Bayer
This article was originally published in The Tan Sheet
Executive SummaryThe Canadian maker of omega-3 phospholipid ingredients announces Bayer Healthcare will commercialize its proprietary products in the U.S. Neptune Technologies & Bioresources credits its "complete portfolio of scientific data, intellectual property and regulatory approvals" with paving the way for the partnership. The firm said June 4 it expects Bayer will help broaden consumer awareness of its products, including Neptune Krill Oil and Advantage NKO dietary supplement. Neptune's strategy is "to penetrate world nutraceutical and pharmaceutical markets" through collaborations with global partners, said Henri Harland, president and CEO for the Laval, Quebec-based company. Neptune previously teamed with Yoplait on functional yogurts and shifted the license for its cardiovascular application portfolio to subsidiary Acasti Pharma (1"The Tan Sheet" Sept. 1, 2008, In Brief)
You may also be interested in...
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?